Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Shares Outstanding (Weighted Average) (2016 - 2025)

Haemonetics (HAE) has 17 years of Shares Outstanding (Weighted Average) data on record, last reported at $47.5 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) fell 5.55% year-over-year to $47.5 million; the TTM value through Dec 2025 reached $47.5 million, down 5.55%, while the annual FY2025 figure was $50.3 million, 0.74% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $47.5 million in Q4 2025 per HAE's latest filing, roughly flat from $47.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $51.2 million in Q3 2022 and bottomed at $47.5 million in Q4 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $50.3 million, with a median of $50.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 1.03% in 2021, then dropped 6.5% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $51.0 million in 2021, then dropped by 0.28% to $50.9 million in 2022, then dropped by 0.43% to $50.7 million in 2023, then fell by 0.78% to $50.3 million in 2024, then fell by 5.55% to $47.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $47.5 million in Q4 2025, $47.6 million in Q3 2025, and $48.1 million in Q2 2025.